Senti Biosciences (SNTI) Leases (2021 - 2025)

Senti Biosciences has reported Leases for 5 years, with the latest figure at $11.5 million in Q4 2025.

• For the quarter ending Q4 2025, Leases fell 17.44% year-over-year to $11.5 million; the trailing twelve-month figure through Dec 2025 stood at $11.5 million (down 17.44% YoY), and the FY2025 full-year result was $11.5 million, down 17.44% from the prior year.
• Leases for Q4 2025 stood at $11.5 million, down from $12.3 million in the prior quarter.
• The five-year high for Leases was $20.7 million in Q4 2021, with the low at $11.5 million in Q4 2025.
• Average Leases over 5 years is $16.0 million, with a median of $16.0 million recorded in 2023.
• Year-over-year, Leases fell 9.88% in 2023 and dropped 17.44% in 2025.
• Tracing SNTI's Leases over 5 years: stood at $20.7 million in 2021, then retreated by 11.06% to $18.4 million in 2022, then retreated by 11.64% to $16.3 million in 2023, then slipped by 14.29% to $13.9 million in 2024, then retreated by 17.44% to $11.5 million in 2025.
• The last three Leases figures came in at $11.5 million (Q4 2025), $12.3 million (Q3 2025), and $12.8 million (Q2 2025), per Business Quant data.

Peer Comparison